The effect of growth hormone treatment on bone mineral density in prepubertal girls with Turner syndrome: a multicentre prospective clinical trial.

What Was Tested

This clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

To determine how GH treatment affects trabecular bone mineral density (BMD) in girls with TS at prepubertal ages in a prospective multicentre study.

Why It Was Studied

Although it is well established that GH promotes longitudinal bone growth, the effects of GH treatment on bone density are less clear.

Who Took Part

By PubMed's age tags, the people studied were young children and children, women only.

Twenty-two patients with TS in the prepubertal period with a mean age of 9.8 +/- 2.5 (range 3.6-12.8) years were included in the study.

All girls with TS underwent measurement of areal BMD using dual-energy X-ray absorptiometry (DXA) to obtain pretreatment anteroposterior (AP) lumbar spine values at L1-L4.

How the Study Was Run

The design is described as multicenter.

More than one site took part, so the participants came from several places.

Lumbar spine BMD Z-scores and volumetric BMD (vBMD) Z-scores were calculated using national standards.

What Was Measured

The subject headings attached to it are Absorptiometry, Photon, Bone Density, Bone Diseases, Metabolic, Human Growth Hormone, Puberty and Turner Syndrome.

What This Means in Plain Language

The paper is a multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2008 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.